PMID- 21061546
OWN - NLM
STAT- MEDLINE
DCOM- 20110120
LR  - 20110727
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 68
IP  - 11
DP  - 2010 Nov
TI  - [Intravenous immunoglobulin (TVIG) therapy in pemphigus].
PG  - 2143-6
AB  - Pemphigus is a rare, chronic, autoimmune mucocutaneous blistering disease. 
      Treatment of pemphigus is often challenging and primarily consists of systemic 
      corticosteroids and various immunosuppressants. When these therapies are used, we 
      should always be careful for the side effects of long-term treatment. Intravenous 
      immunoglobulin (IVIG) is one potential and promising therapy for patients with 
      pemphigus, and evidence of its effectiveness and safety is increasing. A number 
      of pemphigus patients in which IVIG treatment was beneficial have been reported. 
      However, the mode of action of IVIG in autoimmune diseases, including pemphigus, 
      is far from being completely understood. We here summarize the efficacy and 
      safety profile of IVIG in pemphigus, as well as its proposed modes of action.
FAU - Ishii, Norito
AU  - Ishii N
AD  - Department of Dermatology, Kurume University School of Medicine.
FAU - Hashimoto, Takashi
AU  - Hashimoto T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Pemphigus/*therapy
EDAT- 2010/11/11 06:00
MHDA- 2011/01/21 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2010 Nov;68(11):2143-6.